A human IgG1 broadly neutralizing monoclonal antibody engineered with an LS Fc mutation for extended half-life; binds the HIV-1 Env gp120 V2 apex to block viral entry and can mediate Fc-dependent effector functions (ADCC/ADCP).
Human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation for extended half-life (enhanced FcRn binding); binds the HIV-1 Env gp120 V2 apex to neutralize virions and block viral entry, and can engage Fc gamma receptors to mediate ADCC/ADCP against Env-expressing infected cells.
NO
INDIRECT
The antibody binds HIV-1 Env on infected cells and engages Fcγ receptors (including CD32a) on effector cells to mediate ADCC/ADCP, killing Env-expressing cells; CD32a+ cells act as effectors, not targets.
A human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation for extended half-life; targets the HIV-1 Env gp120 CD4 binding site to prevent viral entry and can engage Fc-mediated effector functions.
Human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation to extend half-life; binds the HIV-1 Env gp120 CD4 binding site to neutralize virions and block attachment/entry into CD4+ T cells. Its Fc region can engage Fc gamma receptors to mediate ADCC/ADCP, aiding clearance of Env-expressing infected cells.
YES
DIRECT
The IgG1 bnAb binds gp120 on Env-expressing infected cells and engages Fcγ receptors on NK cells/monocytes to trigger ADCC/ADCP; it can also activate complement (CDC), leading to lysis of the target cell.
A human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation for extended half-life; targets the HIV-1 Env gp120 CD4 binding site to prevent viral entry and can engage Fc-mediated effector functions.
Human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation to extend half-life; binds the HIV-1 Env gp120 CD4 binding site to neutralize virions and block attachment/entry into CD4+ T cells. Its Fc region can engage Fc gamma receptors to mediate ADCC/ADCP, aiding clearance of Env-expressing infected cells.
NO
INDIRECT
VRC07-523LS does not target FcRn for killing; its LS Fc mutation increases FcRn-mediated recycling to prolong half-life. Cytotoxicity (via ADCC/ADCP) is directed at HIV Env-expressing infected cells, not FcRn-expressing cells.
A human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation for extended half-life; targets the HIV-1 Env gp120 CD4 binding site to prevent viral entry and can engage Fc-mediated effector functions.
Human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation to extend half-life; binds the HIV-1 Env gp120 CD4 binding site to neutralize virions and block attachment/entry into CD4+ T cells. Its Fc region can engage Fc gamma receptors to mediate ADCC/ADCP, aiding clearance of Env-expressing infected cells.
NO
INDIRECT
The antibody binds HIV-1 Env on virions/infected cells; its Fc engages CD16a on NK cells to trigger ADCC, which kills Env-expressing infected cells, not the CD16a+ effector cells.
A human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation for extended half-life; targets the HIV-1 Env gp120 CD4 binding site to prevent viral entry and can engage Fc-mediated effector functions.
Human IgG1 broadly neutralizing monoclonal antibody with an LS Fc mutation to extend half-life; binds the HIV-1 Env gp120 CD4 binding site to neutralize virions and block attachment/entry into CD4+ T cells. Its Fc region can engage Fc gamma receptors to mediate ADCC/ADCP, aiding clearance of Env-expressing infected cells.
NO
INDIRECT
The antibody binds HIV-1 Env on infected cells and uses its Fc to engage FcγRIIa on immune effector cells to mediate ADCC/ADCP against Env-expressing targets; FcγRIIa+ cells are not killed—they act as effectors.